COMPASS Pathways plc (CMPS): Cash & Equivalents
$149.61M
As of 2025-12-31
$433.30M
As of 2026-06-30
+1.5%
3-year compound annual growth
-4.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $149.61M | -9.4% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $165.08M | -25.0% | 2026-03-24, Balance as of period end |
| 2023-12-31 | $220.20M | +53.8% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $143.21M | -47.6% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $273.24M | +43.6% | 2024-02-29, Balance as of period end |
| 2020-12-31 | $190.33M | +662.3% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $24.97M | n/a | 2022-02-24, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | 2025-12-31 | $149.61M | -9.4% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $29.64M | -57.2% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $154.97M | -0.3% |
| Abeona Therapeutics Inc. (ABEO) | 2025-12-31 | $78.44M | +235.8% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $110.75M | -35.6% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $80.88M | +45.8% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $44.06M | +171.1% |
| Pliant Therapeutics, Inc. (PLRX) | 2025-12-31 | $45.45M | -36.2% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $53.83M | -38.1% |
Compare CMPS, PBYI, SIGA, ABEO side by side · Screen every company in Pharmaceutical Preparations ↗